In 2012 the European Cardiovascular Research Institute (ECRI) was founded as a European collaborative effort to perform Investigator Sponsored Studies in the field of cardiology.
SYNTAX III Revolution: A randomized study to evaluate the feasibility of Heart-Team clinical decision making regarding the optimal (surgical or percutaneous based) revascularization strategy in patients with complex coronary artery disease.
Dessolve III is a prospective, single-blind (patient), randomized, controlled, multicenter trial. Approximately 17 sites in Europe will participate.
Read more >
TALENT is a prospective multicenter randomized post market all-comer trial to assess the safety and effectiveness of the SUPRAFLEX ...
ABSORB STEMI: the TROFI II Study is one of the first randomized clinical trials which compares the durable polymer based everolimus-eluting XIENCE with the bioresorbable everolimus-eluting...
Read more >
The GLOBAL LEADERS trial is an Investigator-Sponsored Study (ISS) in which 16,000 “all-comer” patients are enrolled in 131 centers in 18 countries in Europe, Australia, Brazil, Canada & Singapore.
Read more >
ECRI provides a structure facilitating trials without the overhead however with the required clinical trial execution expertise.
SYNTAX II is a European multicenter single-arm study investigating the effectiveness of a new generation stent ....
A randomized comparison of a rivaroxaban-based strategy with an antiplatelet-based strategy following successful TAVR for the prevention of leaflet thickening and reduced leaflet motion.
Head Department of Cardiology
Thoraxcenter, Erasmus MC
Great Britain, Oxford
Oxford University Hospital
Spain, Madrid
Hospital Clinico San Carlos
the Netherlands, Amsterdam
Academic Medical Center - University Of Amsterdam
the Netherlands, Amsterdam
Academic Medical Center - University Of Amsterdam
ECRI 2012-2017